Modafinil and Armodafinil: What Differs on the Box

This page used to answer a different question. It was headed “which one is right for you”, and it answered by comparing how the two substances were said to feel: a table of onset and duration, a list of what each was described as doing across a working day, and a decision framework recommending one or the other according to the shape of your schedule. That has been removed on purpose.

Contents

A shop cannot tell you which medicine is right for you — it holds none of your history and has assessed nobody — and the comparison it used to make in place of an assessment was not a comparison of anything printed on either box.

What is left is what is actually written on the two cartons, and it turns out there is more of it than the version this replaces:

• the enantiomer chemistry as composition;
• the strengths as printed;
• which brands exist for each and who makes them;
• what a pharmacopoeial mark on a carton means;
• how to match a pack to a batch analysis;
• what a tablet costs;
• the fact that the legal position is the same for both.

The section explaining exactly why the effect comparison was deleted is near the end, and it is worth reading, because the reason is more interesting than the table was.

The chemistry, described as composition

Modafinil is a chiral compound. Many molecules exist in two mirror-image forms, called enantiomers and labelled R and S: they contain identical atoms joined by identical bonds, but they are not superimposable, in the way that a left hand and a right hand are not.

Modafinil as it is manufactured — the substance in every modafinil brand, in this shop and anywhere else — contains equal parts of the R and the S form. A mixture of that kind is called racemic.

Armodafinil is the same molecule with the R form alone. The name says so: armodafinil, the R-enantiomer isolated. It is not a different substance built from different atoms, and it is not a chemically modified version of modafinil in the way that a fluorinated analogue would be. It is one of the two components of modafinil, presented on its own.

That is a complete description of the difference in composition between the two, and it is the whole of what the chemistry tells you.

It needs the caveat that most writing on this subject leaves out: describing a molecule says nothing about what it does in a body. Knowing that one product contains both mirror forms and the other contains one of them does not tell you how either behaves in a person, how quickly, for how long or how strongly. It tells you what is in the tablet.

Every sentence that slides from the first to the second without a human study in between is speculation wearing a lab coat, and this page does not make that move.

The strengths, as printed

The most visible difference between the two categories is the number on the carton.

• Modafinil is listed here at 200 mg per tablet across every brand.
• Armodafinil is listed at 150 mg per tablet and, in a separate group of brands, at 50 mg per tablet.

Those are declared strengths — what the manufacturer prints on the carton and on the blister foil, and what the batch analysis confirms is in the tablet. They are facts about the product.

No conversion between the two strengths

We do not publish a conversion between them. An earlier version of this page did: it carried a line asserting that a given armodafinil strength was the equivalent of a given modafinil strength. That line is gone and it will not return.

Saying that one strength stands in for another is a statement about quantity, and quantity is a clinical judgement made about a specific person by someone who has assessed them, working from the leaflet packed in the carton. It is not something a shop can state, and a shop that states it anyway is guessing about you in print.

For the same reason we do not publish a price per milligram anywhere on this site, because that arithmetic silently makes the same claim.

The brands, and who makes them

Where two cartons declare the same substance at the same strength, the things left to compare are the company that makes the tablet, the pack sizes offered and the price per tablet. Those are the three things this shop compares, and they are the three things in the tables below.

Prices shown are for the smallest pack currently listed; per-tablet figures fall as pack size rises, and the live figures are on each product page.

Modafinil — 200 mg

Armodafinil — 150 mg

Armodafinil — 50 mg

Read the three tables separately. Price per tablet compares cleanly between pack sizes of the same product, and between brands only where the strength printed on both cartons is identical.

It does not compare across the three groups above, and the 50 mg row being the cheapest per tablet does not make it the better buy — it makes it a different product with a different number on the box. Read the strength off the carton rather than inferring anything from a price column.

What we will and will not say about a manufacturer

For every brand in the three tables we state one thing about its maker: the company name, as printed on the carton.

We do not publish a company history, a market position, a stock listing or a factory certificate for one maker and not for another, because a paragraph of flattering detail attached to a single brand is a ranking whether or not it is written as one — and these tables exist precisely because the brands within a strength differ by maker, excipients, pack size and price and by nothing else.

That rule covers manufacturing standards as well. WHO-GMP is the best known of them: a good-manufacturing-practice standard describing how a production site is run, documented and inspected. Certificates of that kind:

• are held by a site rather than by a product;
• are issued by a national authority for the specific dosage forms listed on the certificate;
• carry an expiry date and have to be renewed;
• say nothing whatever about what a tablet does in a person.

We attach none of them to any product listed here, because we are not the party who can evidence which certificate covers which production line on which date.

The manufacturer and the issuing authority are that party, and a buyer who wants the assurance should ask for the certificate itself and read the scope printed on it.

Nor do we attribute distinctions or markets we cannot evidence, and we will not put a medicines regulator’s name next to any product here.

A factory’s registration with a foreign authority is an administrative listing of an establishment — it is not approval of anything sold from it, and presenting it as though it were is one of the commoner forms of borrowed authority in this market.

And we do not rank makers by size or reputation, because how large a company is, and how often its name comes up, are not properties of the tablet inside the blister.

What is printed on the carton, and how to check it

Both categories ship in the manufacturer’s own sealed packaging: foil blister strips inside the printed carton, with batch number and expiry date exactly as applied at the factory. Nothing is decanted, nothing is relabelled and no blister is cut to make up a quantity, so every tablet delivered traces to a specific batch and to the analysis of that batch.

The printed particulars to look for are the same for modafinil and armodafinil:

• Brand name, substance name and strength — for example “Modafinil Tablets IP 200 mg” or “Armodafinil Tablets IP 150 mg”.
• The pharmacopoeial mark. The suffix IP denotes the Indian Pharmacopoeia, the standard the tablet is manufactured to. Like WHO-GMP it describes how a product is made and tested, and says nothing about what it does in a person.
• Manufacturer name and address and the manufacturing licence number.
• The batch number, repeated on the blister foil.
• Manufacturing date and expiry date, also repeated on the foil, so a loose strip can still be identified.

Batch checks and the certificate of analysis

Every batch arriving at our EU warehouse is sampled and sent for independent laboratory analysis before it is listed, and the Certificate of Analysis for that batch can be downloaded.

The check available to you is:

1. confirm the seal was intact;
2. find the batch number on the carton;
3. confirm the same number is on the foil;
4. then match it to the certificate.

What the certificate states is the identity of the active substance and that the tablet contains the amount declared on the label.

That is worth having — and it is also the limit. It is a document about the contents of a pack, not evidence about an outcome for any person, and we do not present it as though it were.

The legal position is the same for both

This is the point at which people most often expect a difference and there is not one. Modafinil and armodafinil are both prescription-only medicines across the European Union and in the United Kingdom. Neither is an over-the-counter product, neither can lawfully be supplied without a prescription in those markets, and choosing one over the other changes nothing about your legal position.

In most EU member states neither is scheduled under narcotics legislation, and the restriction attaches to supply and dispensing rather than to possession — in the Netherlands, for instance, both are prescription-only under the Geneesmiddelenwet and neither appears on the Opiumwet lists.

Several countries go further and place them in a controlled or habit-forming category with additional rules, and in the United States both are Schedule IV controlled substances. Some countries reserve the initial prescription to specialists.

Import is a separate question again, and it is decided by your country’s medicines and customs rules rather than by a shop’s willingness to dispatch. A customs authority may inspect, detain, refuse entry to or destroy a consignment and write to the addressee about it, and several member states do not permit prescription medicines to be received by post for personal use at all.

Check your own national medicines agency and customs authority before ordering; country guides are published for the Netherlands, Germany, France, Poland, Czechia, Italy and Spain, and they are starting points rather than legal advice.

Competitive sport

One further shared point: both are named on the World Anti-Doping Agency’s Prohibited List among stimulants, as is adrafinil. Holding a prescription does not by itself make a substance permitted in competition, and anyone competing under a code that adopts that list should check with their own anti-doping authority.

What the leaflet covers

Keep two things apart here, because this is the point at which shops in this market blur them. Modafinil and armodafinil are authorised as substances in EU member states. The tablets in the tables above are not. They are generics manufactured in India to the Indian Pharmacopoeia, they hold no EU marketing authorisation of their own, no medicines agency in the Union has assessed them, and what is packed in either carton is the manufacturer’s own leaflet rather than a regulator-approved one.

We relay the manufacturer’s leaflet as exactly that, and we do not promote it in the description.

Where the regulator-agreed documents live

The regulator-agreed documents exist separately, they are public and they are free to read. For each substance, every authorised product has a summary of product characteristics written for prescribers and a patient information leaflet written for the person taking it, both published by the agency that authorised it.

Search a national medicines register for the substance name and open the product information attached to any authorised product:

• CBG-MEB in the Netherlands;
• BfArM in Germany;
• ANSM in France;
• AEMPS in Spain;
• AIFA in Italy;
• URPL in Poland;
• SÚKL in Czechia;
• the MHRA in the United Kingdom.

Those documents carry the complete list of reported effects with their frequencies, the contraindications, the interactions and the warnings.

Note that modafinil and armodafinil have separate documents of their own: one is not a guide to the other, which is a further reason this page declines to treat the two as interchangeable.

What follows is relayed from that published product information, and we grade none of it: no effect here is described as mild, nothing is softened with a reassuring adjective, and nothing is confined to “sensitive people” — that phrasing tells everybody else it will not happen to them, and nobody knows that.

Where this page and a published document differ, the published document is right; where the manufacturer’s leaflet in your carton differs from either, a pharmacist is the person to ask which applies to the pack in your hand.

Reported effects and the urgent-help list

Reported in the published leaflet: headache, nausea, dry mouth, reduced appetite, difficulty sleeping, dizziness, anxiety and nervousness. The published document holds the complete list with frequencies; this summary does not.

Stop and seek urgent medical help if any of the following occur:

• a skin rash, blistering, or ulceration of the mouth or eyes;
• swelling of the face or throat;
• difficulty breathing;
• fever;
• chest pain;
• an irregular heartbeat;
• hallucinations, agitation, confusion, depression or thoughts of self-harm.

A rash can be the first sign of a serious reaction and is a reason to stop and get medical attention, not to wait and see. Severe skin reactions are why these medicines carry a specific warning in several jurisdictions.

Contraindications and cautions. Both are contraindicated in anyone with a known hypersensitivity to modafinil or armodafinil — which is one reason the two are not interchangeable in the way brand-versus-brand within a category is. Medical advice is essential before use by:

• anyone who is pregnant or breastfeeding;
• anyone with a heart condition or high blood pressure;
• anyone with impaired liver or kidney function;
• anyone with a history of psychiatric illness;
• anyone taking other medicines, because interactions are possible.

Hormonal contraception. Both reduce the effectiveness of hormonal contraception, in every form:

• combined pills;
• progestogen-only pills;
• patches;
• implants;
• vaginal rings;
• hormonal intrauterine coils.

Anyone relying on hormonal contraception must agree additional or alternative contraception with a doctor or pharmacist before use, and raise it with them again when stopping rather than assuming the question ends with the last tablet. This is the most under-communicated fact in this category and its consequences cannot be undone.

Pregnancy and breastfeeding. Neither is recommended in pregnancy or while breastfeeding. Anyone who is pregnant, may become pregnant or is breastfeeding must take medical advice before use.

Storage. Keep the tablets in their original packaging at normal room temperature, dry and away from direct light, and out of the sight and reach of children. Do not use after the expiry date printed on the carton and the blister.

We publish no dosing figure, no timing, no administration instruction and no stacking, cycling, switching or alternating protocol for either substance. Suitability and quantity are settled with a doctor or pharmacist working from an individual’s history, their other medicines and the leaflet. Do not combine or alternate medicines without professional advice.

Why the effect comparison has been removed

The version of this article that stood here previously contained:

• a head-to-head table with rows for onset, duration, curve shape, late-day levels and the latest advisable timing;
• a pair of lists describing how each substance was said to feel;
• a statement of dose equivalence between the two strengths;
• a decision framework recommending one or the other according to your working hours and how early you sleep.

Every one of those has been deleted deliberately.

The reason is that the comparison was not a comparison of anything either label contains. A bioequivalent product does not take effect sooner, continue longer or arrive more strongly than another product with the same substance at the same declared strength.

Two 200 mg modafinil cartons from two manufacturers are not two medicines with two personalities, and the tables that score one as smoother and another as sharper are inventing a difference that is not printed anywhere — with the top-scoring row falling, reliably, to whichever product carries the better margin.

Between modafinil and armodafinil the same objection applies with a twist: the composition genuinely differs, so it is tempting to think a table is warranted. It is not, because establishing a difference in how something is experienced requires controlled human comparison, and a shop assembling one out of user reports, forum consensus and its own catalogue is manufacturing an authority it does not have.

Why the dose-equivalence line went too

The dose-equivalence line is the worst of the lot, and it is worth naming separately. Stating that a tablet of one strength stands in for a tablet of another strength is a dosing instruction wearing the costume of a fact. It is exactly the kind of statement that requires an individual assessment, and it was being made here to a reader nobody had assessed.

So this site now publishes no comparison of effect between brands, presentations or substances anywhere in the catalogue, and no ranking by onset, strength or smoothness.

Naming the things we refuse to compare is unavoidable in a passage like this one, and that is fine: a reader who knows which claims a shop has decided it cannot support is better off than one handed a grid that looks authoritative and is not. We compare two things, because they are printed and real — who makes a product, and what it costs per tablet.

Frequently asked questions

What is the actual difference in composition?

Modafinil is a chiral molecule that exists in two mirror-image forms, R and S, and modafinil as manufactured contains equal parts of both. Armodafinil is the same molecule with the R form alone. That is the whole of the difference in composition, and it describes the tablet rather than the experience of taking it.

Why do the cartons print different numbers?

Because they are different products with different declared strengths: modafinil is listed here at 200 mg per tablet, armodafinil at 150 mg and, in a separate set of brands, at 50 mg. Those numbers are what the manufacturer prints and what the batch analysis confirms.

How do the two strengths relate to each other?

We do not publish a conversion, and the line that used to state one has been removed. Relating one strength to another is a statement about quantity, and quantity is a clinical judgement about a specific person made by someone who has assessed them, with the leaflet in front of them. It is not something a shop can state about a reader it has never met.

Which armodafinil brands do you carry?

At 150 mg:

• Artvigil by HAB Pharmaceuticals;
• Walkalarm by Ryon Pharma;
• Vigilant by Taj Pharmaceuticals;
• Armovigil by NATCO Pharma;
• Waklert by Sun Pharma.

At 50 mg:

• Armovin by Taurlib Pharma;
• Armosam by Jagsam Pharma;
• Wakafinil by Pacific India.

The armodafinil category page shows what is in stock today.

Are Waklert and Artvigil the same?

Both declare 150 mg of armodafinil per tablet. Waklert is made by Sun Pharma and Artvigil by HAB Pharmaceuticals, and they are listed at different prices. That is the whole of the difference we will state, because it is the whole of the difference the labels contain.

Is the 50 mg armodafinil better value because it costs less per tablet?

No — the comparison does not hold. Price per tablet compares cleanly between pack sizes of one product, and between brands only where the printed strength is identical. Across different strengths it compares nothing, which is also why we publish no price per milligram anywhere on this site.

Does one of them need a prescription and the other not?

No. Both are prescription-only medicines across the EU and in the UK, and in the United States both are Schedule IV controlled substances. Choosing between them changes nothing about your legal position, and neither can lawfully be supplied without a prescription in those markets.

What does “IP” on the carton mean?

It denotes the Indian Pharmacopoeia — the standard the tablet is manufactured to, printed by the manufacturer because the product is made to that monograph. It is a manufacturing standard describing how something is produced and tested, and it says nothing about what a tablet does in a person.

How do I check the pack I receive?

Confirm the carton seal was intact, find the batch number on the carton, check the same number appears on the blister foil, check the expiry date on both, then obtain the Certificate of Analysis for that batch and confirm the numbers match. The certificate states the identity of the active substance and that the tablet contains the declared amount.

Do they have different side effects?

Each carton arrives with the manufacturer’s own leaflet, which is not a regulator-approved document.

For each substance there is also product information agreed with the agencies that authorised it in EU member states — a summary of product characteristics and a patient leaflet, free to look up in any national medicines register — and modafinil and armodafinil have separate documents of their own.

Those published documents carry the complete list with frequencies, the contraindications and the warnings. We relay them and we do not grade them, and we do not set the two against one another, because ranking one product’s reported effects as milder than another’s is exactly the kind of claim this page no longer makes.

Do both affect hormonal contraception?

Yes. Both reduce the effectiveness of hormonal contraception in every form — combined and progestogen-only pills, patches, implants, vaginal rings and hormonal coils. Agree additional or alternative contraception with a doctor or pharmacist before use, and review it again when stopping.

Can I switch between them, or take both?

We publish no switching, alternating, rotating or combining protocol for either substance, and the “rotation” passage that used to appear here has been removed. Those are questions for a doctor or pharmacist who knows what else you take.

Where has the comparison table gone?

Deleted on purpose. It scored the two substances against each other on onset, duration, curve shape and how each was said to feel, and it stated a dose equivalence between the two strengths. None of that was printed on either carton. This site now compares only manufacturer and price per tablet.

The bottom line

Modafinil and armodafinil differ in composition — both mirror forms of the molecule against one of them — and in the strength printed on the carton.

They do not differ in legal status. Nor in the fact that both substances are authorised in EU member states while the tablets listed here are Indian-Pharmacopoeia generics holding no EU marketing authorisation of their own. Nor in the fact that what arrives in either carton is the manufacturer’s leaflet, with the regulator-agreed product information published separately in the national registers for anyone who wants it. Nor in the answer to the question of who decides whether either is appropriate, which is a doctor and not a website.

What differs and what does not

Everything else this shop can honestly tell you is on the label:

• who made it;
• what standard it was made to;
• what batch it came from;
• what the analysis for that batch says;
• what it costs per tablet.

The modafinil and armodafinil category pages carry the current listings and live prices, and Modafinil in 2026: Legal Status, Brands and What the Carton Says covers the buying and legal ground in more detail.

The other two compounds in this catalogue hold no authorisation at all, and Adrafinil: Legal Status, Manufacturers and What the Label Says and Flmodafinil: What It Is, What Is Known and What Is Not set out precisely what is missing in each case.

Questions this page has not covered are on the FAQ page, or contact us directly. The question we will not answer is which one is right for you — not out of coyness, but because answering it would require knowing things about you that we have made a point of not holding.

NeuroPeak is a shop, not a pharmacy, and this article is not medical advice. Modafinil and armodafinil are prescription-only medicines in most EU countries and controlled substances in several. Import, possession and personal-use rules vary between countries and are amended from time to time — check the rules in force at your delivery address before ordering. Consult a qualified healthcare professional before use.